Literature DB >> 2485067

Influence of local converting enzyme inhibition on angiotensin and bradykinin effects in ischemic rat hearts.

W Linz1, B A Schölkens.   

Abstract

To investigate the influence of local cardiac converting enzyme (CE) inhibition on the effects of angiotensin I (ANG I), ANG II, and bradykinin (BK), experiments were performed in ischemic isolated perfused working rat hearts. Acute regional myocardial ischemia was induced by 15 min occlusion of the left coronary artery followed by reperfusion. In ischemic isolated rat hearts, perfusion with ramiprilat (100 ng/ml, 2.58 x 10(-7) mol/l), the active moiety of the CE inhibitor ramipril, after coronary occlusion protected against ventricular fibrillation that invariably occurred in untreated control hearts in the reperfusion period. Addition of ANG I and ANG II to the perfusate enhanced, whereas BK reduced postischemic reperfusion arrhythmias, which were almost abolished in the hearts from ramipril (1 mg/kg p.o.) pretreated rats. Perfusion with ANG I and ANG II reduced cardiac function and coronary flow, increased the activities of lactate dehydrogenase and creatine kinase in the perfusate, and decreased high-energy-rich phosphates and glycogen in the myocardium. In contrast, BK reduced the enzymatic activities in the perfusate and improved the metabolic parameters in the myocardium. In hearts from ramipril pretreated animals, the ANG I effects were abolished, whereas the ANG II actions remained unchanged. The results of these experiments are consistent with the hypothesis that the beneficial effects of CE inhibitors on ventricular arrhythmias, cardiac function, and metabolism are due to local interference with CE in the coronary vascular wall or heart tissue and subsequent reduction of local ANG II generation and BK degradation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2485067     DOI: 10.1097/00005344-198706107-00012

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Comparison of the effects of ACE inhibition with those of angiotensin II receptor antagonism on systolic and diastolic myocardial stunning in isolated rabbit heart.

Authors:  C Morales; M Rodríguez; O Scapín; R J Gelpi
Journal:  Mol Cell Biochem       Date:  1998-09       Impact factor: 3.396

Review 2.  The renin-angiotensin system and coronary vasomotion.

Authors:  G Ertl; K Hu; W R Bauer; B Bauer
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

3.  Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting-enzyme inhibitor ramipril.

Authors:  W Linz; B A Schölkens; J Kaiser; M Just; B Y Qi; U Albus; P Petry
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

4.  Suppression of the degradation of adenine nucleotides during ischemia may not be a sufficient mechanism for infarct size limitation by preconditioning.

Authors:  T Miura; K Suzuki; K Shimamoto; O Iimura
Journal:  Basic Res Cardiol       Date:  1996 Nov-Dec       Impact factor: 17.165

Review 5.  ACE inhibitors for the treatment of myocardial ischemia?

Authors:  C Linder; G Heusch
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

Review 6.  Cardioprotection by ACE inhibitors in myocardial ischaemia/reperfusion. The importance of bradykinin.

Authors:  G Heusch; J Rose; T Ehring
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 7.  ACE inhibitors in elderly patients with hypertension. Special considerations.

Authors:  M Ravid; D Ravid
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

8.  Protective effects of bradykinin on the ischaemic heart: implication of the B1 receptor.

Authors:  R Chahine; A Adam; N Yamaguchi; R Gaspo; D Regoli; R Nadeau
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

9.  Beneficial effects of bradykinin on porcine ischemic myocardium.

Authors:  R A Tio; T J Tobé; K J Bel; C D de Langen; W H van Gilst; H Wesseling
Journal:  Basic Res Cardiol       Date:  1991 Mar-Apr       Impact factor: 17.165

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.